|
1
|
Liu BL, Zhang X, Zhang W and Zhen HN: New
enlightenment of French Paradox: Resveratrol's potential for cancer
chemoprevention and anti-cancer therapy. Cancer Biol Ther.
6:1833–1836. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meng C, Liu JL and Du AL: Cardioprotective
effect of resveratrol on atherogenic diet-fed rats. Int J Clin Exp
Pathol. 7:7899–7906. 2014.
|
|
3
|
Zheng JP, Ju D, Jiang H, Shen J, Yang M
and Li L: Resveratrol induces p53 and suppresses myocardin-mediated
vascular smooth muscle cell differentiation. Toxicol Lett.
199:115–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smoliga JM, Baur JA and Hausenblas HA:
Resveratrol and health: a comprehensive review of human clinical
trials. Mol Nutr Food Res. 55:1129–1141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aggarwal BB, Bhardwaj A, Aggarwal RS,
Seeram NP, Shishodia S and Takada Y: Role of resveratrol in
prevention and therapy of cancer: Preclinical and clinical studies.
Anticancer Res. 24(5A): 2783–2840. 2004.PubMed/NCBI
|
|
6
|
Athar M, Back JH, Tang X, Kim KH,
Kopelovich L, Bickers DR and Kim AL: Resveratrol: A review of
preclinical studies for human cancer prevention. Toxicol Appl
Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park EJ and Pezzuto JM: The pharmacology
of resveratrol in animals and humans. Biochim Biophys Acta.
1852:1071–1113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Novelle MG, Wahl D, Diéguez C, Bernier M
and de Cabo R: Resveratrol supplementation: Where are we now and
where should we go? Ageing Res Rev. 21:1–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dhar S, Kumar A, Li K, Tzivion G and
Levenson AS: Resveratrol regulates PTEN/Akt pathway through
inhibition of MTA1/HDAC unit of the NuRD complex in prostate
cancer. Biochim Biophys Acta. 1853:265–275. 2015. View Article : Google Scholar
|
|
10
|
Jang M, Cai L, Udeani GO, Slowing KV,
Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta
RG, et al: Cancer chemopreventive activity of resveratrol, a
natural product derived from grapes. Science. 275:218–220. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Ma K, Qi T, Wei X, Zhang Q, Li G
and Chiu JF: P62 regulates resveratrol-mediated Fas/Cav-1 complex
formation and transition from autophagy to apoptosis. Oncotarget.
6:789–801. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu XP, Xiong M, Xu CS, Duan LN, Dong YQ,
Luo Y, Niu TH and Lu CR: Resveratrol induces apoptosis of human
chronic myelogenous leukemia cells in vitro through p38 and
JNK-regulated H2AX phosphorylation. Acta Pharmacol Sin. 36:353–361.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fulda S and Debatin KM: Sensitization for
anticancer drug-induced apoptosis by the chemopreventive agent
resveratrol. Oncogene. 23:6702–6711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta SC, Kannappan R, Reuter S, Kim JH
and Aggarwal BB: Chemosensitization of tumors by resveratrol. Ann
NY Acad Sci. 1215:150–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Türedi S, Yuluğ E, Alver A, Kutlu Ö and
Kahraman C: Effects of resveratrol on doxorubicin induced
testicular damage in rats. Exp Toxicol Pathol. 67:229–235. 2014.
View Article : Google Scholar
|
|
16
|
Zhang L, Guo X, Xie W, Li Y, Ma M, Yuan T
and Luo B: Resveratrol exerts an anti-apoptotic effect on human
bronchial epithelial cells undergoing cigarette smoke exposure. Mol
Med Rep. 11:1752–1758. 2015.
|
|
17
|
Gottesman MM and Ling V: The molecular
basis of multidrug resistance in cancer: The early years of
P-glycoprotein research. FEBS Lett. 580:998–1009. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Colabufo NA, Contino M, Berardi F, Perrone
R, Panaro MA, Cianciulli A, Mitolo V, Azzariti A, Quatrale A and
Paradiso A: A new generation of MDR modulating agents with dual
activity: P-gp inhibitor and iNOS inducer agents. Toxicol In Vitro.
25:222–230. 2011. View Article : Google Scholar
|
|
19
|
Ullah MF: Cancer multidrug resistance
(MDR): A major impediment to effective chemotherapy. Asian Pac J
Cancer Prev. 9:1–6. 2008.PubMed/NCBI
|
|
20
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lage H: An overview of cancer multidrug
resistance: A still unsolved problem. Cell Mol Life Sci.
65:3145–3167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nitiss JL: DNA topoisomerase II and its
growing repertoire of biological functions. Nat Rev Cancer.
9:327–337. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Burgess DJ, Doles J, Zender L, Xue W, Ma
B, McCombie WR, Hannon GJ, Lowe SW and Hemann MT: Topoisomerase
levels determine chemotherapy response in vitro and in vivo. Proc
Natl Acad Sci USA. 105:9053–9058. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Järvinen TA and Liu ET: Topoisomerase
IIalpha gene (TOP2A) amplification and deletion in cancer - more
common than anticipated. Cytopathology. 14:309–313. 2003.
View Article : Google Scholar
|
|
25
|
Carrato A, Falcone A, Ducreux M, Valle JW,
Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C and
Parthenaki I: A Systematic review of the burden of pancreatic
cancer in europe: Real-world impact on survival, quality of life
and costs. J Gastrointest Cancer. 46:201–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boyle J, Czito B, Willett C and Palta M:
Adjuvant radiation therapy for pancreatic cancer: A review of the
old and the new. J Gastrointest Oncol. 6:436–444. 2015.PubMed/NCBI
|
|
27
|
Xu Q, Zong L, Chen X, Jiang Z, Nan L, Li
J, Duan W, Lei J, Zhang L, Ma J, et al: Resveratrol in the
treatment of pancreatic cancer. Ann NY Acad Sci. 1348:10–19. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shankar S, Nall D, Tang SN, Meeker D,
Passarini J, Sharma J and Srivastava RK: Resveratrol inhibits
pancreatic cancer stem cell characteristics in human and KrasG12D
transgenic mice by inhibiting pluripotency maintaining factors and
epithelial-mesenchymal transition. PLoS One. 6:e165302011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lage H, Jordan A, Scholz R and Dietel M:
Thermosensitivity of multidrug-resistant human gastric and
pancreatic carcinoma cells. Int J Hyperthermia. 16:291–303. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Skehan P, Storeng R, Scudiero D, Monks A,
McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR:
New colorimetric cytotoxicity assay for anticancer-drug screening.
J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lage H and Dietel M: Multiple mechanisms
confer different drug-resistant phenotypes in pancreatic carcinoma
cells. J Cancer Res Clin Oncol. 128:349–357. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Harikumar KB and Aggarwal BB: Resveratrol:
A multitargeted agent for age-associated chronic diseases. Cell
Cycle. 7:1020–1035. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cui J, Sun R, Yu Y, Gou S, Zhao G and Wang
C: Antiproliferative effect of resveratrol in pancreatic cancer
cells. Phytother Res. 24:1637–1644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang G, Dai F, Yu K, Jia Z, Zhang A, Huang
Q, Kang C, Jiang H and Pu P: Resveratrol inhibits glioma cell
growth via targeting oncogenic microRNAs and multiple signaling
pathways. Int J Oncol. 46:1739–1747. 2015.PubMed/NCBI
|
|
37
|
Gatouillat G, Balasse E, Joseph-Pietras D,
Morjani H and Madoulet C: Resveratrol induces cell-cycle disruption
and apoptosis in chemoresistant B16 melanoma. J Cell Biochem.
110:893–902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chin YT, Hsieh MT, Yang SH, Tsai PW, Wang
SH, Wang CC, Lee YS, Cheng GY, HuangFu WC, London D, et al:
Anti-proliferative and gene expression actions of resveratrol in
breast cancer cells in vitro. Oncotarget. 5:12891–12907. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nabekura T, Kamiyama S and Kitagawa S:
Effects of dietary chemopreventive phytochemicals on P-glycoprotein
function. Biochem Biophys Res Commun. 327:866–870. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Quan F, Pan C, Ma Q, Zhang S and Yan L:
Reversal effect of resveratrol on multidrug resistance in KBv200
cell line. Biomed Pharmacother. 62:622–629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Borska S, Sopel M, Chmielewska M, Zabel M
and Dziegiel P: Quercetin as a potential modulator of
P-glycoprotein expression and function in cells of human pancreatic
carcinoma line resistant to daunorubicin. Molecules. 15:857–870.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Borska S, Chmielewska M, Wysocka T,
Drag-Zalesinska M, Zabel M and Dziegiel P: In vitro effect of
quercetin on human gastric carcinoma: Targeting cancer cells death
and MDR. Food Chem Toxicol. 50:3375–3383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leone S, Basso E, Polticelli F and Cozzi
R: Resveratrol acts as a topoisomerase II poison in human glioma
cells. Int J Cancer. 131:E173–E178. 2012. View Article : Google Scholar
|
|
44
|
Leone S, Cornetta T, Basso E and Cozzi R:
Resveratrol induces DNA double-strand breaks through human
topoisomerase II interaction. Cancer Lett. 295:167–172. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schroeter A and Marko D: Resveratrol
modulates the topoisomerase inhibitory potential of doxorubicin in
human colon carcinoma cells. Molecules. 19:20054–20072. 2014.
View Article : Google Scholar : PubMed/NCBI
|
